Hair loss hope: new drink targets shedding from popular Weight-Loss meds
NCT ID NCT07484061
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily drinkable supplement called Olistic Next Women to see if it can reduce hair loss in women over 35 who are taking GLP-1/GIP weight-loss drugs. Forty participants will be randomly assigned to receive either the supplement or a placebo for 6 months. The main goal is to measure changes in hair shedding using a patient-reported scale and a comb-and-wash test.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TELOGEN EFFLUVIUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Grupo Dermatologico Y Estetico Pedro Jaen S.A.
RECRUITINGMadrid, Madrid, 28006, Spain
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.